AMLX Amylyx Pharmaceuticals
- 1.720
- +0.040+2.38%
- 1.680
- -0.040-2.33%
Amylyx Pharmaceuticals News
Analysts Conflicted on These Healthcare Names: Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals Inc (AMLX) and Vaxcyte (PCVX)
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Wave Life Sciences (WVE) and GoodRx Holdings (GDRX)
Amylyx Pharma Analyst Ratings
Mizuho Maintains Neutral on Amylyx Pharma, Lowers Price Target to $3
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), IN8bio (INAB) and Privia Health Group (PRVA)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
HC Wainwright & Co. : Amylyx Pharma (AMLX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Amylyx Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Amylyx Pharmaceuticals Inc (AMLX) and Rhythm Pharmaceuticals (RYTM)
Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects
HC Wainwright & Co. : Amylyx Pharma (AMLX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Amylyx Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Amylyx Pharma, Maintains $8 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharma Analyst Ratings
Amylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue Impact
Deutsche Bank Cuts Amylyx Pharmaceuticals' Price Target to $4 From $8, Maintains Buy Rating
Amylyx Pharmaceuticals Hold Rating: Navigating Setbacks With a Strategic Pivot and Long-Term Potential
Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline Developments
Analysis
Price Target
No Data
